Search Result
Results for "
Amylases
" in MedChemExpress (MCE) Product Catalog:
7
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N0419
-
Quercetin-7-O-β-D-glucopyranoside
|
Others
|
Metabolic Disease
|
Quercimeritrin, isolated from the leaves of Ixeridium dentatum, exhibits significant amylase activity .
|
-
-
- HY-P0039
-
|
Bombesin Receptor
|
Cancer
|
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer .
|
-
-
- HY-149557
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
-
- HY-155241
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
-
- HY-146752
-
|
Others
|
Others
|
α-Amylase-IN-1 is a potent α-amylase inhibitor with an IC50 of 4.46 μM .
|
-
-
- HY-157537
-
-
-
- HY-146225
-
|
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent α-amylase and α-glucosidase dual inhibitor with IC50 values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .
|
-
-
- HY-153101
-
|
Biochemical Assay Reagents
|
Others
|
Gal-G2-CNP, a galactopyranosylmaltoside, can be used as substrate for the determination of novel amylase and pancreatic amylase .
|
-
-
- HY-147711
-
|
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent α-amylase/α-glucosidase inhibitor with IC50s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .
|
-
-
- HY-P2770
-
|
Others
|
Others
|
β-Amylase, Bacilus subtilis has abundant starch degrading activities. β-Amylase can be used for various biochemical studies .
|
-
-
- HY-149973
-
|
Others
|
Metabolic Disease
|
α-Amylase-IN-4 (Compd 10y) show maximum inhibition of amylase activity with IC50 value 17.83 ± 0.14 μg/mL .
|
-
-
- HY-162169
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC50 = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .
|
-
-
- HY-149313
-
|
Amylases
|
Metabolic Disease
|
α Amylase-IN-1 (Compound 11) is an α-Amylase inhibitor with an IC50 value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC50 value of 53.49 μM for scavenging DPPH free radicals. IC50 can be used in the study of diabetes and oxidative stress-related diseases.
|
-
-
- HY-154972
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .
|
-
-
- HY-156380
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .
|
-
-
- HY-149008
-
|
Amylases
|
Metabolic Disease
Cancer
|
α-Amylase-IN-3 (Compound 4) is a none-competitive type of α-Amylase inhibitor with an IC50 value of 18.04 μM, which also has radical scavenging activities (DPPH and ABTS) with IC50 values of 16.04 μM (DPPH) and 16.99 μM (ABTS), respectively. α-Amylase-IN-3 has good protein–ligand interactions profile against α-Amylase. α-Amylase-IN-3 may have pharmacological activities such as anti-oxidative, anti-inflammatory inhibitory, which is helpful for the development of diabetes and oxidative stress associated disease .
|
-
-
- HY-162036
-
|
Glucosidase
Amylases
Cholinesterase (ChE)
|
Neurological Disease
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and α-amylase enzyme inhibitor with IC50 values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC50 values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .
|
-
-
- HY-135530
-
|
Amylases
|
Metabolic Disease
|
Chinese gallotannin is a non-specific promiscuous α-amylase inhibitor with a Ki of 0.82 μg/mL for human salivary α-amylase. Chinese gallotannin can be used for the research of diabetes .
|
-
-
- HY-112835
-
pNP-G7
|
Amylases
|
Others
|
Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside (pNP-G7) is the substrate of α-amylase. Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside can be used to measure a-amylase activity .
|
-
-
- HY-N7729
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
|
-
-
- HY-161355
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both α-amylase (IC50 = 16.4 μM) and α-glucosidase (IC50 = 31.6 μM) enzymes .
|
-
-
- HY-162373
-
|
Amylases
Glucosidase
P-glycoprotein
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
|
-
-
- HY-P2968
-
|
Amylases
|
Others
|
Bacterial α-Amylase catalyses the hydrolysis of internal α-1,4-glycosidic linkages in starch in low molecular weight products, such glucose, maltose and maltotriose units. Bacterial α-Amylase is often used in biochemical studies .
|
-
-
- HY-N2464
-
-
-
- HY-132179
-
-
-
- HY-N12263
-
|
Amylases
|
Metabolic Disease
|
3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of α-Amylase with the inhibitory activity of 28.3% at 500 μM .
|
-
-
- HY-N11844
-
|
Amylases
|
Metabolic Disease
|
Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC50 of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .
|
-
-
- HY-146981
-
-
-
- HY-E70183
-
EC:3.2.1.20; GAA
|
Biochemical Assay Reagents
|
Others
|
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
|
-
-
- HY-N1425
-
|
|
|
Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of α-amylase with a Ki value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .
|
-
-
- HY-N10413
-
|
Glucosidase
|
Metabolic Disease
|
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and α-amylase inhibitor with IC50s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .
|
-
-
- HY-W727627
-
|
Amylases
|
Metabolic Disease
|
5-O-Coumaroylquinic acid is a potent, reversible, non-competitive α-amylase inhibitor with an IC50 value of 69.39 μM. 5-O-Coumaroylquinic acid can be used in diabetes research .
|
-
-
- HY-146984
-
|
Glucosidase
|
Inflammation/Immunology
|
α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivative against α-glucosidase (IC50=1.28 µM) and α-amylase (IC50=3.8 µM) .
|
-
-
- HY-N10064
-
|
Others
|
Metabolic Disease
|
Ficusonolide has significant antidiabetic activity with a possible mechanism of interaction with dipeptidyl peptidase-IV (DPP-IV), protein tyrosine phosphatase 1B (PTP-1B), α-glucosidase, and α-amylase.
|
-
-
- HY-143268
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively .
|
-
-
- HY-N0668
-
|
GLUT
Amylases
NF-κB
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
|
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
-
- HY-143269
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively .
|
-
-
- HY-P1096
-
|
Cholecystokinin Receptor
|
Metabolic Disease
|
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .
|
-
-
- HY-153102
-
|
Biochemical Assay Reagents
|
Others
|
G3-CNP is an α-amylase substrate. The absorbance of G3-CNP cleavage product 2-chloro-4-nitrophenol is measured at 405 nm, which can be used to detect enzyme activity .
|
-
-
- HY-P3899
-
|
Somatostatin Receptor
|
Metabolic Disease
|
[Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) increases the amylase release.[Nle8] Somatostatin (1-28) increases the cyclic AMP in pancreatic acini .
|
-
-
- HY-E70118
-
|
Others
|
Others
|
Oligo-1,6-glucosidase belongs to the α-amylase family that catalyzes the exo hydrolysis of α-1,6-glucoside bonds from the nonreducing ends of panose, palatinose, α-limit dextrins, and isomaltooligosaccharides .
|
-
-
- HY-N1425R
-
|
Others
|
Metabolic Disease
|
Tiliroside (Standard) is the analytical standard of Tiliroside. This product is intended for research and analytical applications. Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of α-amylase with a Ki value of 84.2? μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .
|
-
-
- HY-N12650
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Kaempferol 3-O-alpha-L-(2, 3-di-Z-p-coumaroyl) rhamnoside (compound 42) is a flavonol that can be isolated from Platanus Occidentalis. Kaempferol 3-O-alpha-L-(2, 3-di-Z-p-coumaroyl) rhamnoside is an inhibitor of alpha-amylase and DPP IV .
|
-
-
- HY-Y0598
-
|
|
|
trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and α-amylase inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity .
|
-
-
- HY-N10360
-
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
Ellipyrone A, a γ-pyrone enclosed macrocyclic poyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.35 mM). Ellipyrone A also has anti-carbolytic property against α-glucosidase (IC50=0.74 mM) and α-amylase (IC50=0.59 mM) .
|
-
-
- HY-N9916
-
|
Amylases
|
Metabolic Disease
|
8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside (Compound 3) is natural product that can be isolated from Bidens bipinnata. 8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside shows 22% inhibition against α-amylase at 0.556 mg/mL .
|
-
-
- HY-155961
-
-
-
- HY-N12688
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
2,3-Dihydrocalodenin B (Compound 6) is a compound that can be isolated from Knema globularia. 2,3-Dihydrocalodenin B is a potent and non-competitive inhibitor against α-glucosidase and α-amylase, with IC50 values of 1.1 and 2.6 μM, respectively. 2,3-Dihydrocalodenin B can be used for the research of diabetes .
|
-
-
- HY-126052
-
|
COX
Tyrosinase
HDAC
|
Metabolic Disease
Cancer
|
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .
|
-
- HY-N11728
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual α-amylase/α-glucosidase inhibitor with IC50 values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .
|
-
- HY-W068682
-
Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin
|
Amylases
Bacterial
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
1-Hydroxyphenazine (Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin) is an inhibitor for α-Amylase with an IC50 of 3.1 μg/mL . 1-Hydroxyphenazine exhibits anticancer and anti-inflammatory activity against cells A549, 1321N1 and RAW264.7, antifungal and antibacterial activity against strains Candida albicans, Aspergillus fumigatus, Escherichia coli and Xanthomonas campestris .
|
-
- HY-101764
-
SR 27897
|
Cholecystokinin Receptor
|
Metabolic Disease
|
Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .
|
-
- HY-N6805
-
Acetyl isoeugenol
|
Cholinesterase (ChE)
|
Inflammation/Immunology
Cancer
|
Isoeugenol acetate (Acetyl isoeugenol), an essential oil constituent of nutmeg, clove, and cinnamon, shows excellent inhibitory effects against some metabolic enzymes such as acetylcholinesterase (AChE) enzymes (IC50=77 nM; Ki=16 nM), α-glycosidase (IC50=19.25 nM; Ki=21 nM), and α-amylase (IC50=411.5 nM). Isoeugenol acetate is used medical and cosmetics industries for its antioxidant, anticancer, antimicrobial and anti-inflammatory properties .
|
-
- HY-N2278
-
Leachianone E
|
Tyrosinase
Glucosidase
|
Cancer
|
Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC50 and Kivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .
|
-
- HY-N8161
-
Kaempferol 3,7-diglucoside
|
Glucosidase
Cholinesterase (ChE)
|
Neurological Disease
|
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside), a flavonol, possesses enzyme inhibition property towards α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3,7-di-O-β-glucoside protects differentiating neuronal cells, SH-SY5Y from Amyloid β peptide-induced injury. Kaempferol-3,7-di-O-β-glucoside has the potential for Alzheimer's research .
|
-
- HY-N8134
-
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one is a natural product found in the leaves and stem bark of M. glabra. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one displays binding affinities with dipeptidyl peptidase-4 (DPP-4) and α-Amylase. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one has potential antidiabetic activities .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-B2192
-
|
Biochemical Assay Reagents
|
Amylase is an enzyme produced by pancreas and salivary glands, catalyzing the hydrolysis of starch into sugars. Amylase are broadly classified into α, β, and γ subtypes .
|
-
- HY-P2762
-
|
Biochemical Assay Reagents
|
α-Amylase from Aspergillus oryzae is an amylase. α-Amylase from Aspergillus oryzae can be used for various biochemical studies .
|
-
- HY-153101
-
|
Enzyme Substrates
|
Gal-G2-CNP, a galactopyranosylmaltoside, can be used as substrate for the determination of novel amylase and pancreatic amylase .
|
-
- HY-P2968
-
|
Biochemical Assay Reagents
|
Bacterial α-Amylase catalyses the hydrolysis of internal α-1,4-glycosidic linkages in starch in low molecular weight products, such glucose, maltose and maltotriose units. Bacterial α-Amylase is often used in biochemical studies .
|
-
- HY-E70183
-
EC:3.2.1.20; GAA
|
Enzyme Substrates
|
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
|
-
- HY-B2193
-
|
Biochemical Assay Reagents
|
α-Amylase is a hydrolase enzyme that catalyses the hydrolysis of internal α-1, 4-glycosidic linkages in starch to yield products like glucose and maltose.
|
-
- HY-153102
-
|
Enzyme Substrates
|
G3-CNP is an α-amylase substrate. The absorbance of G3-CNP cleavage product 2-chloro-4-nitrophenol is measured at 405 nm, which can be used to detect enzyme activity .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3377
-
|
Peptides
|
Inflammation/Immunology
|
Rimtoregtide is a polypeptide compound which significantly reduces the increase in the levels of amylase and lipase in the blood caused by acute pancreatitis. Rimtoregtide has the potential for the research of pancreatitis and acute pancreatitis (extracted from patent WO2018205233A1).
|
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P1096
-
|
Cholecystokinin Receptor
|
Metabolic Disease
|
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .
|
-
- HY-P0039
-
|
Bombesin Receptor
|
Cancer
|
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer .
|
-
- HY-P1133
-
Rat galanin(2-29)
|
Peptides
|
Others
|
Galanin (2-29) (rat) inhibits rat pancreatic protein and CCK-8-stimulated amylase secretion. Galanin (2-29) (rat) is an GAL2R agonist (Ki: 3.5 nM) .
|
-
- HY-P3899
-
|
Somatostatin Receptor
|
Metabolic Disease
|
[Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) increases the amylase release.[Nle8] Somatostatin (1-28) increases the cyclic AMP in pancreatic acini .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: